1. Natural history of autoimmune primary ovarian insufficiency in patients with Addison's disease: from normal ovarian function to overt ovarian dysfunction.
- Author
-
De Bellis, Annamaria, Bellastella, Giuseppe, Falorni, Alberto, Aitella, Ernesto, Barrasso, Mariluce, Ida Maiorino, Maria, Bizzarro, Elio, Bellastella, Antonio, Giugliano, Dario, and Esposito, Katherine
- Subjects
PREMATURE ovarian failure ,ADDISON'S disease ,IMMUNOGLOBULINS - Abstract
Context: Women with autoimmune Addison's disease with normal ovulatory cycles but positive for steroid cell antibodies (StCA) have been considered at risk of premature ovarian insufficiency (POI). Design: Thirty-three women younger than 40 years, with subclinical-clinical autoimmune Addison's disease but with normally ovulatory menses, were followed up for 10 years to evaluate the long-term time-related variations of StCA, ovarian function and follicular reserve. All patients and 27 control women were investigated at the start and every year for the presence and titre of StCA (by indirect immunofluorescence), serum concentrations of anti-Mullerian hormone (AMH) and ovarian function at four consecutive menses every year. Results: At the start of the study StCA were present in 16 women (group 1), at low/middle titres (≥1:32) in seven of them (43.8%, group 1A), at high titres (>1:32) in the remaining nine patients (group 1B, 56.2%), while they were absent from 17 patients (group 2). During the follow-up period, all women in group 1A remained StCA-positive at low/middle titres with normal ovulatory menses and normal gonadotrophin and AMH levels, while all patients in group 1B showed a further increase of StCA titres (1:128-1:256) and progressed through three stages of ovarian function. None of the patients in group 2 and controls showed the appearance of StCA or ovarian dysfunction during the follow-up. Conclusions: The presence of StCA at high titres can be considered a good predictive marker of subsequent development of autoimmune POI. To single out the stages of autoimmune POI may allow a timely therapeutic choice in the subclinical and early clinical stages. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF